Carvolix Reports Successful Postmarketing Results for TAVIPILOT AI Software
Carvolix announced the completion of its SAITO postmarketing clinical program evaluating the TAVIPILOT software used during Transcatheter Aortic Valve Implantation procedures. The program included three studies involving 30 patients across France and Australia.
The company reported a 100 percent procedural success rate and high clinician satisfaction with the software. TAVIPILOT assists medical teams in precise positioning of heart valves during implantation and has received clearance for commercial use in the United States.
The positive results from the SAITO program support broader clinical adoption of TAVIPILOT as a guidance tool for valve placement. Carvolix also published its 2025 Universal Registration Document and confirmed an extension of its cash runway through additional funding.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Oct 16 Study Tests Smartphone AI for Children's Lung Sounds Oct 16 Manhattan Physician Invests in RunPractice Oct 16 Attilio appoints Buck Institute CEO Eric Verdin as cochairman Oct 16 Aignostics launches HETA Clinical for pathology workflows Oct 16 Specialty1 Partners Invests in AI for Dental Practice OperationsLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
AbbVie Partners With Valkai on AI Tools for Clinical Development
SimBioSys Gets FDA Clearance for AI Breast Cancer Recurrence Tool
Tucuvi Joins Microsoft Pegasus Program
TRI Launches TRIAL.OS for Clinical Trial Management
Rhythm AI Study Reports 90% Freedom From Atrial Fibrillation
Daily AI Brief: the AI news that matters, in your inbox.